176 related articles for article (PubMed ID: 35353020)
1. Role of dalbavancin as combination therapy: evidence from the literature and clinical scenarios.
Cacopardo B; Cattaneo D; Cortese F; Di Luca M; Falcone M; Marchetti G; Tascini C; Tiseo G; Venditti M
Expert Rev Anti Infect Ther; 2022 Jul; 20(7):997-1004. PubMed ID: 35353020
[TBL] [Abstract][Full Text] [Related]
2. Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.
Garnock-Jones KP
Drugs; 2017 Jan; 77(1):75-83. PubMed ID: 27988870
[TBL] [Abstract][Full Text] [Related]
3. The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives.
Andreoni M; Bassetti M; Corrao S; De Rosa FG; Esposito V; Falcone M; Grossi P; Pea F; Petrosillo N; Tascini C; Venditti M; Viale P
Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1125-1134. PubMed ID: 33682593
[TBL] [Abstract][Full Text] [Related]
4. Experience with dalbavancin use in various gram-positive infections within Aberdeen Royal Infirmary OPAT service.
McSorley JC; Reyes D; Tonna I; Bateman V
Infection; 2024 Apr; 52(2):567-576. PubMed ID: 38165594
[TBL] [Abstract][Full Text] [Related]
5. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
Ramdeen S; Boucher HW
Expert Opin Pharmacother; 2015; 16(13):2073-81. PubMed ID: 26239321
[TBL] [Abstract][Full Text] [Related]
6. Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.
Gatti M; Andreoni M; Pea F; Viale P
Drug Des Devel Ther; 2021; 15():3349-3378. PubMed ID: 34376971
[TBL] [Abstract][Full Text] [Related]
7. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.
Tobudic S; Forstner C; Burgmann H; Lagler H; Steininger C; Traby L; Vossen MG; Winkler S; Thalhammer F
Infection; 2019 Dec; 47(6):1013-1020. PubMed ID: 31520397
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of dalbavancin alone and in combination with β-lactam antibiotics against resistant phenotypes of Staphylococcus aureus.
Xhemali X; Smith JR; Kebriaei R; Rice SA; Stamper KC; Compton M; Singh NB; Jahanbakhsh S; Rybak MJ
J Antimicrob Chemother; 2019 Jan; 74(1):82-86. PubMed ID: 30260409
[TBL] [Abstract][Full Text] [Related]
9. The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).
Soriano A; Rossolini GM; Pea F
Expert Rev Anti Infect Ther; 2020 May; 18(5):415-422. PubMed ID: 32223465
[No Abstract] [Full Text] [Related]
10. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.
Turco NJ; Kane-Gill SL; Hernandez I; Oleksiuk LM; D'Amico F; Pickering AJ
Expert Opin Pharmacother; 2018 Mar; 19(4):319-325. PubMed ID: 29509504
[TBL] [Abstract][Full Text] [Related]
11. French national cohort of first use of dalbavancin: A high proportion of off-label use.
Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of clinical evidence for dalbavancin].
Rodríguez-Pardo D
Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():33-37. PubMed ID: 28129819
[TBL] [Abstract][Full Text] [Related]
13. Successful Treatment of Diabetic Foot Osteomyelitis with Dalbavancin.
Loupa CV; Lykoudi E; Meimeti E; Moisoglou I; Voyatzoglou ED; Kalantzi S; Konsta E
Med Arch; 2020 Jun; 74(3):243-245. PubMed ID: 32801445
[TBL] [Abstract][Full Text] [Related]
14. Dalbavancin in the treatment of acute bacterial skin and skin structure and other infections: a safety evaluation.
Righi E; Visentin A; Meroi M; Carrara E; Tacconelli E
Expert Opin Drug Saf; 2022 Sep; 21(9):1171-1181. PubMed ID: 36093622
[TBL] [Abstract][Full Text] [Related]
15. Current trends in the real-life use of dalbavancin: report of a study panel.
Durante-Mangoni E; Gambardella M; Iula VD; De Stefano GF; Corrado MF; Esposito V; Gentile I; Coppola N
Int J Antimicrob Agents; 2020 Oct; 56(4):106107. PubMed ID: 32721599
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study).
Bai F; Aldieri C; Cattelan A; Raumer F; Di Meco E; Moioli MC; Tordato F; Morelli P; Borghi F; Rizzi M; Van Hauwermeiren E; Castelli F; Migliorino G; Menzaghi B; Rizzardini G; Saracino A; Cascio A; Puoti M; d'Arminio Monforte A; Marchetti G
Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1271-1279. PubMed ID: 32797758
[TBL] [Abstract][Full Text] [Related]
17. Role or oritavancin and dalbavancin in acute bacterial skin and skin structure infections and other potential indications.
Bassetti M; Labate L; Vena A; Giacobbe DR
Curr Opin Infect Dis; 2021 Apr; 34(2):96-108. PubMed ID: 33405480
[TBL] [Abstract][Full Text] [Related]
18. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review.
Thomas G; Henao-Martínez AF; Franco-Paredes C; Chastain DB
Int J Antimicrob Agents; 2020 Sep; 56(3):106069. PubMed ID: 32603683
[TBL] [Abstract][Full Text] [Related]
19. The role of dalbavancin in skin and soft tissue infections.
Bassetti M; Peghin M; Carnelutti A; Righi E
Curr Opin Infect Dis; 2018 Apr; 31(2):141-147. PubMed ID: 29298166
[TBL] [Abstract][Full Text] [Related]
20. Cost-Consequence Analysis of Single-Dose Dalbavancin Versus Standard of Care for the Treatment of Acute Bacterial Skin and Skin Structure Infections in a Multisite Healthcare System.
Gonzalez J; Andrade DC; Niu J
Clin Infect Dis; 2021 Oct; 73(7):e1436-e1442. PubMed ID: 33211794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
